With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...

Truist Securities increased the price target for Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ: VRTX), a $121 ...

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Vertex Minerals Limited engages in evaluation and exploration of minerals in Australia. It primarily explores for gold, lithium, and nickel. Vertex Minerals Limited was incorporated in 2021 and is ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

The highest price of Vertex Securities Ltd stock is ₹7.36 in the last 52-week ... key details MSCI India rejig: Adani Green Energy out, Hyundai Motor in; Jai Corp sees smallcap index exclusion ...

This anticipated adoption, along with a projected modest market penetration, underpins the increased price target for Vertex Pharmaceuticals’ stock, contributing to Fein’s Buy rating.